AUA 2025, bladder cancer, EORTC risk prediction model, CUETO risk prediction model, Blue Light Cystoscopy (BLC), trans urethral resection of bladder tumor (TURBT), blue light-guided trans urethral resection of bladder tumor (BLC-TURBT).
AUA 2025, prostate cancer, 18F-DCFPyL, 18F-FDG PET/CT, Heterogeneity of Advanced Prostate Cancer by 18F-DCFPyL and 18F-FDG PET/CT, dual-tracer (¹⁸F-DCFPyL and ¹⁸F-FDG) PET/CT imaging.
AUA 2025, upper tract urothelial carcinoma (UTUC), Tislelizumab, humanized IgG4 anti-PD-1 monoclonal antibody.
AUA 2025, kidney cancer, renal cell carcinoma (RCC), metastatic renal cell carcinoma (mRCC), Nivolumab, Ipilimumab, Nivolumab plus Ipilimumab Therapy, sunitinib, Primary Resistance to Nivolumab plus…
AUA 2025 KEYNOTE-564 trial, clear cell renal cell carcinoma (ccRCC), adjuvant pembrolizumab, partial nephrectomy,
AUA 2025 PSMA-PET imaging to stage men with prostate cancer, regional lymph node involvement, distant metastases, preoperative PSMA-PET imaging, Michigan Urological Surgery Improvement Collaborative (MUSIC),
AUA 2025, Prostate Cancer, Prostate Cancer Risk Groups by PSMA-PET PROMISE (PPP), Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), PROMISE registry.
AUA 2025, prostate cancer, metastatic castration-sensitive prostate cancer (mCSPC), androgen receptor pathway inhibitors (ARPIs), Homologous Recombination Repair (HRR), Homologous Recombination Repair Alterations, AMPLITUDE trial, TALAPRO-3…
AUA 2025, Metastatic Castration-Resistant Prostate Cancer (mCRPC), 177Lu-PSMA Therapy, 225Ac-J591 PSMA-Targeted Radionuclide Therapy, 225Ac-J591 PSMA-Targeted Radionuclide Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with Prior…
AUA 2025, non–muscle-invasive bladder cancer (NMIBC), TAR-200 monotherapy, SunRISe-1 trial, BCG-unresponsive disease.
AUA 2025 advanced prostate cancer, results of SOAR, phase II trial of image-guided oligometastasectomy and radiation therapy in recurrent prostate cancer patients.
